Business Wire

SOSAFE-GMBH

7.2.2024 09:01:27 CET | Business Wire | Press release

Share
Andrew Rose Appointed as Chief Security Officer at Leading Security Awareness Vendor SoSafe

SoSafe, Europe’s leading vendor for security awareness, behavior, and culture change, today announced the appointment of Andrew Rose as its new Chief Security Officer (CSO). With a wealth of experience in the industry, Rose is a highly accomplished cyber security executive with a strong focus on the people-centric aspects of cyber security.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240207094549/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Andrew Rose appointed as new Chief Security Officer at leading security awareness vendor SoSafe (Photo: Business Wire)

In his role as CSO, Rose will focus on driving SoSafe’s vision to strengthen digital self-defense worldwide and help customers transform their security culture. He’ll also bring hands-on experience, knowledge, and perspective in managing risk and improving cyber security posture across complex enterprises.

Recognized for his outstanding contributions to the field, Rose was awarded the prestigious title of 'European CISO of the Year 2018' at the SC Awards, and has been a part of the CSO30 every year since its inception in 2020. Across his career, Rose has transformed security management for multiple major organizations in the legal, aviation, technology, and finance sectors.

Notably, Rose held the position as Resident CISO at Proofpoint Inc., where he helped customers enhance their security practices, cultivated a community of CISOs and represented the brand externally. Prior to that, he oversaw the cyber security of UK airspace traffic at NATS and managed the secure processing of trillions of pounds in transfers at Vocalink, a Mastercard company. He also worked at Forrester Research, where he was Principal Analyst covering the awareness and culture change space and developed influential models for the security awareness industry. In 2015, when Rose implemented the models he had designed at Forrester, he was awarded ‘UK Awareness Campaign of the Year’ at the UK Cyber Security Awards. Rose also has an established record in the legal sector with over a decade as CISO at 'magic circle' firms Clifford Chance LLP and Allen & Overy LLP.

Niklas Hellemann, Psychologist and CEO of SoSafe, remarked: "Andrew’s expertise is a perfect match for our mission at SoSafe. In an era where AI-powered cyber threats are escalating, Andrew's extensive industry experience is invaluable in leading our efforts to be the global industry leader in fortifying the human aspect of cyber security.”

Rose's decision to join SoSafe was driven by the company's unwavering focus on addressing the critical problem of the underestimated human factor in cyber security. “There is a huge imbalance in focus as the biggest part of security budgets are dedicated to security technology while according to the World Economic Forum, 95% of cyber threats have a human element involved. SoSafe’s commitment to strengthening the human factor, coupled with their innovative use of behavioral science and technology, aligns perfectly with my vision.”

“SoSafe’s approach to security awareness is unique in the industry: Having a CEO with a background in psychology means that the human-centric perspective is deeply rooted in their DNA. They focus on behavioral science to tackle the problem and then use technology to enable the solution”, Rose stated.

By joining SoSafe, Andrew Rose will further strengthen the company's position as a leader in the industry. With his track record of success and commitment to driving secure behavior in organizations, Andrew Rose is poised to make a significant contribution to the company's ongoing mission of strengthening digital self-defense.

About SoSafe

SoSafe empowers organizations to build a security culture and mitigate risk with its GDPR-compliant awareness programs. The company was founded in Cologne, Germany, in 2018 by Dr Niklas Hellemann, Lukas Schaefer, and Felix Schuerholz. Today, it serves more than 4500 customers worldwide and is the market leader in security awareness and training in the DACH region. As one of the leading second-generation awareness platforms, they are powered by behavioral science and smart algorithms and focus on user engagement and the needs of the customer. In doing so, SoSafe delivers engaging, personalized learning experiences and smart attack simulations that turn employees into active assets against online threats. The SoSafe team consists of more than 370 employees at seven locations: Cologne (headquarters), Amsterdam, Berlin, Lisbon, London, Munich, and Paris.

Website: www.sosafe-awareness.com/
LinkedIn: www.linkedin.com/company/sosafe-cyber-security/mycompany/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240207094549/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye